Prostate Cancer

Predicting and Preventing Prostate Cancer Spread

University of Adelaide researchers have uncovered a new pathway which regulates the spread of prostate cancer around the body.

Model of research findings
Model of research findings
Source: Luke Selth

Published in the journal Cancer Research, the discovery has potential to lead to the development of a blood test that could predict whether cancer will spread from the prostate tumour to other parts of the body. The research also reveals potential new targets for drugs that may inhibit the spread of cancer.

“Prostate cancers only kill men after they have spread or ‘metastasised’ from the prostate,” says project leader Dr Luke Selth, Senior Research Fellow at the University of Adelaide‘s Dame Roma Mitchell Cancer Research Laboratories and a member of the Freemasons Foundation Centre for Men’s Health.

“The identification of markers that accurately predict, at an early stage, prostate tumours that are likely to metastasise could guide the urgency and aggressiveness of treatment – and this could save lives.”

The international research team – led by the University of Adelaide and including members from the University of Michigan, Vancouver Prostate Centre, the Mayo Clinic and Johns Hopkins University – showed that a specific microRNA (a type of molecule involved in regulating the level and activity of genes) called miR-194 promotes cancer metastasis by inhibiting a key protein called SOCS2. SOCS2 can suppress the spread of cancer cells.

“In previous work, we had found that a high level of miR-194 in a patient’s blood was associated with rapid relapse of prostate cancer following surgical removal of the tumour,” says Dr Selth. “This new work explains why miR-194 is associated with a poor outcome, and in the process reveals a completely novel pathway regulating prostate cancer metastasis.

“Importantly, measuring miR-194 in a patient’s blood at the time of diagnosis could become a test for the likelihood of metastasis. Patients with high levels of miR-194 in their blood could receive more aggressive treatment to reduce the chance of the cancer spreading to other parts of the body.” Dr Selth’s team is currently testing this idea using larger patient groups to validate their findings.

Dr Selth says miR-194 also represents a potential therapeutic target. “There are currently no drugs that effectively inhibit the spread of prostate cancer,” he says. “We propose that inhibiting miR-194 could reduce rates of metastasis in patients with aggressive disease, but the development of a drug to achieve this goal is still a long way off.”

This work was supported by funding from the National Health and Medical Research Council of Australia, the Prostate Cancer Foundation (USA), the Freemasons Foundation Centre for Men’s Health, the Prostate Cancer Foundation of Australia and Movember.

Source: newswise

06.02.2017

Read all latest stories

Related articles

Study

Novel biomarker test accurately predicting high-grade prostate cancer

ProteoMediX AG announced results from a retrospective study that showed the correlation of its prostate cancer diagnosis test with cancer aggressiveness in patients scheduled for prostate biopsies.…

External and brachytherapy

Prostate cancer: Combination of radiation therapies key to success

Prostate cancer is one of the most common cancers diagnosed nationally among men. The National Cancer Institute estimates 161,000 were diagnosed in 2017. While there are many treatment options for…

Beyond PSA monitoring

New prostate cancer risk model could better guide treatment

One of the biggest challenges in treating prostate cancer is distinguishing men who have aggressive and potentially lethal disease from men whose cancer is slow-growing and unlikely to metastasize.…

Related products

Immunochemistry

Beckman Coulter - phi (Prostate Health Index)

Beckman Coulter, Inc.

Research use only (RUO)

Eppendorf - Mastercycler nexus X2

Eppendorf AG

MRT Coils

NORAS Uni-Lift Prostate Intervention Device

NORAS MRI products GmbH

Research use only (RUO)

SARSTEDT - Low DNA Binding Micro Tubes

SARSTEDT AG & CO.

Research use only (RUO)

Shimadzu - CLAM-2000

Shimadzu Europa GmbH